{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T19:32:39Z","timestamp":1793302359755,"version":"4.5.0"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2023,10,11]],"date-time":"2023-10-11T00:00:00Z","timestamp":1696982400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,10,11]],"date-time":"2023-10-11T00:00:00Z","timestamp":1696982400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Aberrant overexpression or activation of EGFR drives the development of non-small cell lung cancer (NSCLC) and acquired resistance to EGFR tyrosine kinase inhibitors (TKIs) by secondary EGFR mutations or c-MET amplification\/activation remains as a major hurdle for NSCLC treatment. We previously identified WDR4 as a substrate adaptor of Cullin 4 ubiquitin ligase and an association of WDR4 high expression with poor prognosis of lung cancer. Here, using an unbiased ubiquitylome analysis, we uncover PTPN23, a component of the ESCRT complex, as a substrate of WDR4-based ubiquitin ligase. WDR4-mediated PTPN23 ubiquitination leads to its proteasomal degradation, thereby suppressing lysosome trafficking and degradation of wild type EGFR, EGFR mutant, and c-MET. Through this mechanism, WDR4 sustains EGFR and c-MET signaling to promote NSCLC proliferation, migration, invasion, stemness, and metastasis. Clinically, PTPN23 is downregulated in lung cancer and its low expression correlates with WDR4 high expression and poor prognosis. Targeting WDR4-mediated PTPN23 ubiquitination by a peptide that competes with PTPN23 for binding WDR4 promotes EGFR and c-MET degradation to block the growth and progression of EGFR TKI-resistant NSCLC. These findings identify a central role of WDR4\/PTPN23 axis in EGFR and c-MET trafficking and a potential therapeutic target for treating EGFR TKI-resistant NSCLC.<\/jats:p>","DOI":"10.1038\/s41419-023-06201-4","type":"journal-article","created":{"date-parts":[[2023,10,11]],"date-time":"2023-10-11T12:02:04Z","timestamp":1697025724000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["PTPN23 ubiquitination by WDR4 suppresses EGFR and c-MET degradation to define a lung cancer therapeutic target"],"prefix":"10.1038","volume":"14","author":[{"given":"Shaifali","family":"Singh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nai Yang","family":"Yeat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya-Ting","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu-Yu","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I-Ying","family":"Kuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1525-6004","authenticated-orcid":false,"given":"Kuen-Phon","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9733-0839","authenticated-orcid":false,"given":"Won-Jing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Ching","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wu-Chou","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7694-2067","authenticated-orcid":false,"given":"Yi-Ching","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8124-5832","authenticated-orcid":false,"given":"Ruey-Hwa","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,10,11]]},"reference":[{"key":"6201_CR1","doi-asserted-by":"publisher","first-page":"15009","DOI":"10.1038\/nrdp.2015.9","volume":"1","author":"C Gridelli","year":"2015","unstructured":"Gridelli C, Rossi A, Carbone DP, Guarize J, Karachaliou N, Mok T, et al. Non-small-cell lung cancer. Nat Rev Dis Primers. 2015;1:15009.","journal-title":"Nat Rev Dis Primers"},{"key":"6201_CR2","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21654","volume":"71","author":"RL Siegel","year":"2021","unstructured":"Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistics, 2021. CA Cancer J Clin. 2021;71:7\u201333.","journal-title":"CA Cancer J Clin"},{"key":"6201_CR3","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1007\/s00109-014-1165-y","volume":"92","author":"A Gower","year":"2014","unstructured":"Gower A, Wang Y, Giaccone G. Oncogenic drivers, targeted therapies, and acquired resistance in non-small-cell lung cancer. J Mol Med (Berl). 2014;92:697\u2013707.","journal-title":"J Mol Med (Berl)"},{"key":"6201_CR4","doi-asserted-by":"publisher","first-page":"2380","DOI":"10.1056\/NEJMoa0909530","volume":"362","author":"M Maemondo","year":"2010","unstructured":"Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 2010;362:2380\u20138.","journal-title":"N Engl J Med"},{"key":"6201_CR5","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S1470-2045(09)70364-X","volume":"11","author":"T Mitsudomi","year":"2010","unstructured":"Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsurutani J, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol. 2010;11:121\u20138.","journal-title":"Lancet Oncol"},{"key":"6201_CR6","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1126\/science.1099314","volume":"304","author":"JG Paez","year":"2004","unstructured":"Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004;304:1497\u2013500.","journal-title":"Science"},{"key":"6201_CR7","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/S1470-2045(11)70393-X","volume":"13","author":"R Rosell","year":"2012","unstructured":"Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012;13:239\u201346.","journal-title":"Lancet Oncol"},{"key":"6201_CR8","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/S1470-2045(11)70184-X","volume":"12","author":"C Zhou","year":"2011","unstructured":"Zhou C, Wu YL, Chen G, Feng J, Liu XQ, Wang C, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2011;12:735\u201342.","journal-title":"Lancet Oncol"},{"key":"6201_CR9","doi-asserted-by":"publisher","first-page":"75ra26","DOI":"10.1126\/scitranslmed.3002003","volume":"3","author":"LV Sequist","year":"2011","unstructured":"Sequist LV, Waltman BA, Dias-Santagata D, Digumarthy S, Turke AB, Fidias P, et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med. 2011;3:75ra26.","journal-title":"Sci Transl Med"},{"key":"6201_CR10","doi-asserted-by":"publisher","first-page":"2240","DOI":"10.1158\/1078-0432.CCR-12-2246","volume":"19","author":"HA Yu","year":"2013","unstructured":"Yu HA, Arcila ME, Rekhtman N, Sima CS, Zakowski MF, Pao W, et al. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin Cancer Res. 2013;19:2240\u20137.","journal-title":"Clin Cancer Res"},{"key":"6201_CR11","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1158\/2159-8290.CD-14-0337","volume":"4","author":"DA Cross","year":"2014","unstructured":"Cross DA, Ashton SE, Ghiorghiu S, Eberlein C, Nebhan CA, Spitzler PJ, et al. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov. 2014;4:1046\u201361.","journal-title":"Cancer Discov"},{"key":"6201_CR12","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1056\/NEJMoa1413654","volume":"372","author":"LV Sequist","year":"2015","unstructured":"Sequist LV, Soria JC, Goldman JW, Wakelee HA, Gadgeel SM, Varga A, et al. Rociletinib in EGFR-mutated non-small-cell lung cancer. N Engl J Med. 2015;372:1700\u20139.","journal-title":"N Engl J Med"},{"key":"6201_CR13","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.jtho.2019.11.005","volume":"15","author":"AJ Schoenfeld","year":"2020","unstructured":"Schoenfeld AJ, Yu HA. The Evolving Landscape of Resistance to Osimertinib. J Thorac Oncol. 2020;15:18\u201321.","journal-title":"J Thorac Oncol"},{"key":"6201_CR14","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1038\/nm.3854","volume":"21","author":"KS Thress","year":"2015","unstructured":"Thress KS, Paweletz CP, Felip E, Cho BC, Stetson D, Dougherty B, et al. Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M. Nat Med. 2015;21:560\u20132.","journal-title":"Nat Med"},{"key":"6201_CR15","doi-asserted-by":"publisher","first-page":"20932","DOI":"10.1073\/pnas.0710370104","volume":"104","author":"J Bean","year":"2007","unstructured":"Bean J, Brennan C, Shih JY, Riely G, Viale A, Wang L, et al. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci USA. 2007;104:20932\u20137.","journal-title":"Proc Natl Acad Sci USA"},{"key":"6201_CR16","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1126\/science.1141478","volume":"316","author":"JA Engelman","year":"2007","unstructured":"Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science. 2007;316:1039\u201343.","journal-title":"Science."},{"key":"6201_CR17","doi-asserted-by":"publisher","first-page":"i10","DOI":"10.1093\/annonc\/mdx703","volume":"29","author":"D Westover","year":"2018","unstructured":"Westover D, Zugazagoitia J, Cho BC, Lovly CM, Paz-Ares L. Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors. Ann Oncol. 2018;29:i10\u2013i9.","journal-title":"Ann Oncol"},{"key":"6201_CR18","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.ddtec.2019.01.002","volume":"31","author":"M Pettersson","year":"2019","unstructured":"Pettersson M, Crews CM. PROteolysis TArgeting Chimeras (PROTACs) - past, present and future. Drug Discov Today Technol. 2019;31:15\u201327.","journal-title":"Drug Discov Today Technol."},{"key":"6201_CR19","doi-asserted-by":"publisher","first-page":"100647","DOI":"10.1016\/j.jbc.2021.100647","volume":"296","author":"SB Alabi","year":"2021","unstructured":"Alabi SB, Crews CM. Major advances in targeted protein degradation: PROTACs, LYTACs, and MADTACs. J Biol Chem. 2021;296:100647.","journal-title":"J Biol Chem"},{"key":"6201_CR20","doi-asserted-by":"publisher","first-page":"4087","DOI":"10.1242\/jcs.209197","volume":"130","author":"J Bakker","year":"2017","unstructured":"Bakker J, Spits M, Neefjes J, Berlin I. The EGFR odyssey - from activation to destruction in space and time. J Cell Sci. 2017;130:4087\u201396.","journal-title":"J Cell Sci"},{"key":"6201_CR21","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.ceb.2011.03.008","volume":"23","author":"HW Platta","year":"2011","unstructured":"Platta HW, Stenmark H. Endocytosis and signaling. Curr Opin Cell Biol. 2011;23:393\u2013403.","journal-title":"Curr Opin Cell Biol"},{"key":"6201_CR22","doi-asserted-by":"publisher","first-page":"7279","DOI":"10.1128\/MCB.22.20.7279-7290.2002","volume":"22","author":"Y Wang","year":"2002","unstructured":"Wang Y, Pennock S, Chen X, Wang Z. Endosomal signaling of epidermal growth factor receptor stimulates signal transduction pathways leading to cell survival. Mol Cell Biol. 2002;22:7279\u201390.","journal-title":"Mol Cell Biol"},{"key":"6201_CR23","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2121-10-84","volume":"10","author":"BM Chung","year":"2009","unstructured":"Chung BM, Raja SM, Clubb RJ, Tu C, George M, Band V, et al. Aberrant trafficking of NSCLC-associated EGFR mutants through the endocytic recycling pathway promotes interaction with Src. BMC Cell Biol. 2009;10:84.","journal-title":"BMC Cell Biol"},{"key":"6201_CR24","doi-asserted-by":"publisher","first-page":"806","DOI":"10.5306\/wjco.v5.i5.806","volume":"5","author":"BM Chung","year":"2014","unstructured":"Chung BM, Tom E, Zutshi N, Bielecki TA, Band V, Band H. Nexus of signaling and endocytosis in oncogenesis driven by non-small cell lung cancer-associated epidermal growth factor receptor mutants. World J Clin Oncol. 2014;5:806\u201323.","journal-title":"World J Clin Oncol"},{"key":"6201_CR25","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.devcel.2011.05.015","volume":"21","author":"WM Henne","year":"2011","unstructured":"Henne WM, Buchkovich NJ, Emr SD. The ESCRT pathway. Dev Cell. 2011;21:77\u201391.","journal-title":"Dev Cell"},{"key":"6201_CR26","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1038\/nrm2937","volume":"11","author":"JH Hurley","year":"2010","unstructured":"Hurley JH, Hanson PI. Membrane budding and scission by the ESCRT machinery: it\u2019s all in the neck. Nat Rev Mol Cell Biol. 2010;11:556\u201366.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"6201_CR27","doi-asserted-by":"publisher","first-page":"6308","DOI":"10.1073\/pnas.0707601105","volume":"105","author":"A Doyotte","year":"2008","unstructured":"Doyotte A, Mironov A, McKenzie E, Woodman P. The Bro1-related protein HD-PTP\/PTPN23 is required for endosomal cargo sorting and multivesicular body morphogenesis. Proc Natl Acad Sci USA. 2008;105:6308\u201313.","journal-title":"Proc Natl Acad Sci USA"},{"key":"6201_CR28","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/j.cub.2013.02.033","volume":"23","author":"N Ali","year":"2013","unstructured":"Ali N, Zhang L, Taylor S, Mironov A, Urbe S, Woodman P. Recruitment of UBPY and ESCRT exchange drive HD-PTP-dependent sorting of EGFR to the MVB. Curr Biol. 2013;23:453\u201361.","journal-title":"Curr Biol"},{"key":"6201_CR29","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.1016\/j.str.2016.10.006","volume":"24","author":"D Gahloth","year":"2016","unstructured":"Gahloth D, Levy C, Heaven G, Stefani F, Wunderley L, Mould P, et al. Structural basis for selective interaction between the ESCRT regulator HD-PTP and UBAP1. Structure. 2016;24:2115\u201326.","journal-title":"Structure."},{"key":"6201_CR30","doi-asserted-by":"publisher","first-page":"e0149113","DOI":"10.1371\/journal.pone.0149113","volume":"11","author":"J Lee","year":"2016","unstructured":"Lee J, Oh KJ, Lee D, Kim BY, Choi JS, Ku B, et al. Structural Study of the HD-PTP Bro1 domain in a complex with the core region of STAM2, a subunit of ESCRT-0. PLoS One. 2016;11:e0149113.","journal-title":"PLoS One"},{"key":"6201_CR31","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1042\/BST20170443","volume":"46","author":"L Tabernero","year":"2018","unstructured":"Tabernero L, Woodman P. Dissecting the role of His domain protein tyrosine phosphatase\/PTPN23 and ESCRTs in sorting activated epidermal growth factor receptor to the multivesicular body. Biochem Soc Trans. 2018;46:1037\u201346.","journal-title":"Biochem Soc Trans"},{"key":"6201_CR32","doi-asserted-by":"crossref","unstructured":"Parkinson G, Roboti P, Zhang L, Taylor S, Woodman P. His domain protein tyrosine phosphatase and Rabaptin-5 couple endo-lysosomal sorting of EGFR with endosomal maturation. J Cell Sci. 2021;134:jcs259192","DOI":"10.1242\/jcs.259192"},{"key":"6201_CR33","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/j.celrep.2015.09.024","volume":"13","author":"D Kharitidi","year":"2015","unstructured":"Kharitidi D, Apaja PM, Manteghi S, Suzuki K, Malitskaya E, Roldan A, et al. Interplay of endosomal pH and ligand occupancy in integrin alpha5beta1 ubiquitination, endocytic sorting, and cell migration. Cell Rep. 2015;13:599\u2013609.","journal-title":"Cell Rep"},{"key":"6201_CR34","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1016\/j.cellsig.2015.07.020","volume":"27","author":"H Ma","year":"2015","unstructured":"Ma H, Wardega P, Mazaud D, Klosowska-Wardega A, Jurek A, Engstrom U, et al. Histidine-domain-containing protein tyrosine phosphatase regulates platelet-derived growth factor receptor intracellular sorting and degradation. Cell Signal. 2015;27:2209\u201319.","journal-title":"Cell Signal"},{"key":"6201_CR35","first-page":"4841","volume":"125","author":"DY Chen","year":"2012","unstructured":"Chen DY, Li MY, Wu SY, Lin YL, Tsai SP, Lai PL, et al. The Bro1-domain-containing protein Myopic\/HDPTP coordinates with Rab4 to regulate cell adhesion and migration. J Cell Sci. 2012;125:4841\u201352.","journal-title":"J Cell Sci"},{"key":"6201_CR36","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1101\/gad.2018911","volume":"25","author":"G Lin","year":"2011","unstructured":"Lin G, Aranda V, Muthuswamy SK, Tonks NK. Identification of PTPN23 as a novel regulator of cell invasion in mammary epithelial cells from a loss-of-function screen of the \u2018PTP-ome\u2019. Genes Dev. 2011;25:1412\u201325.","journal-title":"Genes Dev"},{"key":"6201_CR37","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.1016\/j.celrep.2016.04.076","volume":"15","author":"S Manteghi","year":"2016","unstructured":"Manteghi S, Gingras MC, Kharitidi D, Galarneau L, Marques M, Yan M, et al. Haploinsufficiency of the ESCRT component HD-PTP predisposes to cancer. Cell Rep. 2016;15:1893\u2013900.","journal-title":"Cell Rep"},{"key":"6201_CR38","doi-asserted-by":"publisher","first-page":"2982","DOI":"10.1172\/JCI89957","volume":"127","author":"YT Wang","year":"2017","unstructured":"Wang YT, Chen J, Chang CW, Jen J, Huang TY, Chen CM, et al. Ubiquitination of tumor suppressor PML regulates prometastatic and immunosuppressive tumor microenvironment. J Clin Invest. 2017;127:2982\u201397.","journal-title":"J Clin Invest"},{"key":"6201_CR39","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1126\/science.1250255","volume":"346","author":"JP Theurillat","year":"2014","unstructured":"Theurillat JP, Udeshi ND, Errington WJ, Svinkina T, Baca SC, Pop M, et al. Prostate cancer. Ubiquitylome analysis identifies dysregulation of effector substrates in SPOP-mutant prostate cancer. Science. 2014;346:85\u20139.","journal-title":"Science"},{"key":"6201_CR40","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1261\/rna.2030705","volume":"11","author":"A Alexandrov","year":"2005","unstructured":"Alexandrov A, Grayhack EJ, Phizicky EM. tRNA m7G methyltransferase Trm8p\/Trm82p: evidence linking activity to a growth phenotype and implicating Trm82p in maintaining levels of active Trm8p. RNA. 2005;11:821\u201330.","journal-title":"RNA."},{"key":"6201_CR41","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1017\/S1355838202024019","volume":"8","author":"A Alexandrov","year":"2002","unstructured":"Alexandrov A, Martzen MR, Phizicky EM. Two proteins that form a complex are required for 7-methylguanosine modification of yeast tRNA. RNA. 2002;8:1253\u201366.","journal-title":"RNA."},{"key":"6201_CR42","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-015-0779-x","volume":"16","author":"R Shaheen","year":"2015","unstructured":"Shaheen R, Abdel-Salam GM, Guy MP, Alomar R, Abdel-Hamid MS, Afifi HH, et al. Mutation in WDR4 impairs tRNA m(7)G46 methylation and causes a distinct form of microcephalic primordial dwarfism. Genome Biol. 2015;16:210.","journal-title":"Genome Biol"},{"key":"6201_CR43","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1096\/fj.11-197723","volume":"26","author":"J Lefebvre","year":"2012","unstructured":"Lefebvre J, Ancot F, Leroy C, Muharram G, Lemiere A, Tulasne D. Met degradation: more than one stone to shoot a receptor down. FASEB J. 2012;26:1387\u201399.","journal-title":"FASEB J"},{"key":"6201_CR44","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1038\/ncb0901-802","volume":"3","author":"SY Lin","year":"2001","unstructured":"Lin SY, Makino K, Xia W, Matin A, Wen Y, Kwong KY, et al. Nuclear localization of EGF receptor and its potential new role as a transcription factor. Nat Cell Biol. 2001;3:802\u20138.","journal-title":"Nat Cell Biol"},{"key":"6201_CR45","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.ccr.2005.05.007","volume":"7","author":"HW Lo","year":"2005","unstructured":"Lo HW, Hsu SC, Ali-Seyed M, Gunduz M, Xia W, Wei Y, et al. Nuclear interaction of EGFR and STAT3 in the activation of the iNOS\/NO pathway. Cancer Cell. 2005;7:575\u201389.","journal-title":"Cancer Cell"},{"key":"6201_CR46","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.ccr.2008.03.015","volume":"13","author":"Z Weihua","year":"2008","unstructured":"Weihua Z, Tsan R, Huang WC, Wu Q, Chiu CH, Fidler IJ, et al. Survival of cancer cells is maintained by EGFR independent of its kinase activity. Cancer Cell. 2008;13:385\u201393.","journal-title":"Cancer Cell"},{"key":"6201_CR47","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.lungcan.2020.07.014","volume":"147","author":"S Schmid","year":"2020","unstructured":"Schmid S, Li JJN, Leighl NB. Mechanisms of osimertinib resistance and emerging treatment options. Lung Cancer. 2020;147:123\u20139.","journal-title":"Lung Cancer"},{"key":"6201_CR48","doi-asserted-by":"publisher","first-page":"103274","DOI":"10.1016\/j.isci.2021.103274","volume":"24","author":"JM Kazan","year":"2021","unstructured":"Kazan JM, Desrochers G, Martin CE, Jeong H, Kharitidi D, Apaja PM, et al. Endofin is required for HD-PTP and ESCRT-0 interdependent endosomal sorting of ubiquitinated transmembrane cargoes. iScience. 2021;24:103274.","journal-title":"iScience"},{"key":"6201_CR49","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1042\/BST20160332","volume":"45","author":"MC Gingras","year":"2017","unstructured":"Gingras MC, Kazan JM, Pause A. Role of ESCRT component HD-PTP\/PTPN23 in cancer. Biochem Soc Trans. 2017;45:845\u201354.","journal-title":"Biochem Soc Trans"},{"key":"6201_CR50","doi-asserted-by":"publisher","first-page":"a016949","DOI":"10.1101\/cshperspect.a016949","volume":"5","author":"I Mellman","year":"2013","unstructured":"Mellman I, Yarden Y. Endocytosis and cancer. Cold Spring Harb Perspect Biol. 2013;5:a016949.","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"6201_CR51","doi-asserted-by":"publisher","first-page":"2132","DOI":"10.15252\/embj.201591518","volume":"34","author":"CR Reis","year":"2015","unstructured":"Reis CR, Chen PH, Srinivasan S, Aguet F, Mettlen M, Schmid SL. Crosstalk between Akt\/GSK3beta signaling and dynamin-1 regulates clathrin-mediated endocytosis. EMBO J. 2015;34:2132\u201346.","journal-title":"EMBO J"},{"key":"6201_CR52","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1016\/j.devcel.2017.01.007","volume":"40","author":"PH Chen","year":"2017","unstructured":"Chen PH, Bendris N, Hsiao YJ, Reis CR, Mettlen M, Chen HY, et al. Crosstalk between CLCb\/Dyn1-mediated adaptive clathrin-mediated endocytosis and epidermal growth factor receptor signaling increases metastasis. Dev Cell. 2017;40:278\u201388.e5.","journal-title":"Dev Cell"},{"key":"6201_CR53","doi-asserted-by":"publisher","first-page":"E9570","DOI":"10.1073\/pnas.1810209115","volume":"115","author":"GY Xiao","year":"2018","unstructured":"Xiao GY, Mohanakrishnan A, Schmid SL. Role for ERK1\/2-dependent activation of FCHSD2 in cancer cell-selective regulation of clathrin-mediated endocytosis. Proc Natl Acad Sci USA. 2018;115:E9570\u2013E9579.","journal-title":"Proc Natl Acad Sci USA"},{"key":"6201_CR54","doi-asserted-by":"publisher","first-page":"e3000778","DOI":"10.1371\/journal.pbio.3000778","volume":"18","author":"GY Xiao","year":"2020","unstructured":"Xiao GY, Schmid SL. FCHSD2 controls oncogenic ERK1\/2 signaling outcome by regulating endocytic trafficking. PLoS Biol. 2020;18:e3000778.","journal-title":"PLoS Biol"},{"key":"6201_CR55","doi-asserted-by":"crossref","unstructured":"Chiang SY, Wu HC, Lin SY, Chen HY, Wang CF, Yeh NH, et al. Usp11 controls cortical neurogenesis and neuronal migration through Sox11 stabilization. Sci Adv. 2021;7:eabc6093.","DOI":"10.1126\/sciadv.abc6093"},{"key":"6201_CR56","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-21715-1","volume":"12","author":"YH Chen","year":"2021","unstructured":"Chen YH, Huang TY, Lin YT, Lin SY, Li WH, Hsiao HJ, et al. VPS34 K29\/K48 branched ubiquitination governed by UBE3C and TRABID regulates autophagy, proteostasis and liver metabolism. Nat Commun. 2021;12:1322.","journal-title":"Nat Commun"},{"key":"6201_CR57","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.ccr.2011.07.008","volume":"20","author":"WC Yuan","year":"2011","unstructured":"Yuan WC, Lee YR, Huang SF, Lin YM, Chen TY, Chung HC, et al. A Cullin3-KLHL20 ubiquitin ligase-dependent pathway targets PML to potentiate HIF-1 signaling and prostate cancer progression. Cancer Cell. 2011;20:214\u201328.","journal-title":"Cancer Cell"},{"key":"6201_CR58","doi-asserted-by":"crossref","unstructured":"Johnson S, Chen H, Lo PK. In vitro Tumorsphere Formation Assays. Bio Protoc. 2013;3:e325.","DOI":"10.21769\/BioProtoc.325"}],"updated-by":[{"DOI":"10.1038\/s41419-024-06747-x","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2024,7,2]],"date-time":"2024-07-02T00:00:00Z","timestamp":1719878400000}}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-023-06201-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-023-06201-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-023-06201-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,3]],"date-time":"2024-07-03T03:03:16Z","timestamp":1719975796000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-023-06201-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,11]]},"references-count":58,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2023,10]]}},"alternative-id":["6201"],"URL":"https:\/\/doi.org\/10.1038\/s41419-023-06201-4","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,11]]},"assertion":[{"value":"5 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 October 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2024","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41419-024-06747-x","URL":"https:\/\/doi.org\/10.1038\/s41419-024-06747-x","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All mouse experiments were conducted according to the guidelines of animal ethical regulations and approved by the Experimental Animal Committee, Academia Sinica, Taiwan. All studies using human tissues were approved by the Institutional Review Boards of Academia Sinica and National Cheng Kung University. Informed consent forms were received from patients prior to their inclusion in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}],"article-number":"671"}}